Ratings Adocia

Equities

ADOC

FR0011184241

Market Closed - Euronext Paris Other stock markets 11:35:07 2024-04-29 EDT			5-day change	1st Jan Change
8.36 ^EUR	-0.83%		-1.07%	-27.56%

04-24	Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-22	Adocia: announces fund-raising	CF

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
The company has a low valuation given the cash flows generated by its activity.
For several months, analysts have been revising their EPS estimates roughly upwards.

Weaknesses

The company's enterprise value to sales, at 6.62 times its current sales, is high.
The company appears highly valued given the size of its balance sheet.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ADOCIA	-27.56%	129M	-
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	103B	B+
REGENERON PHARMACEUTICALS, INC.	+1.62%	95.28B	B+
ARGENX SE	+1.46%	22.15B	B
BIONTECH SE	-16.67%	21.02B	B+
GENMAB A/S	-8.58%	18.15B	A-
WUXI APPTEC CO., LTD.	-38.74%	16.73B	A-
BEIGENE, LTD.	-13.21%	16.05B	B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.68B	C+
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes